QiHuangYiShen Granules Modulate the Expression of LncRNA MALAT1 and Attenuate Epithelial-Mesenchymal Transition in Kidney of Diabetic Nephropathy Rats
暂无分享,去创建一个
Ning Zhang | Kaifeng Shi | Tongzhong Li | Xiang-fei Meng | Qiu-yue Ren | Li-sha Yuan | Hua Du | Rong-lu Yang | Shi-Wei Liu | Shi-Yi Liu | Bo Wang
[1] Guanchi Yan,et al. The Impact of lncRNA on Diabetic Kidney Disease: Systematic Review and In Silico Analyses , 2022, Computational intelligence and neuroscience.
[2] C. Maher,et al. Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.
[3] Zhenying Ge,et al. lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p/IL6ST Axis , 2021, Frontiers in Pharmacology.
[4] A. Kourtidis,et al. LNCcation: lncRNA localization and function , 2021, The Journal of cell biology.
[5] Lingling Zhang,et al. Tanshinone IIA Ameliorates Streptozotocin-Induced Diabetic Nephropathy, Partly by Attenuating PERK Pathway-Induced Fibrosis , 2020, Drug design, development and therapy.
[6] Qingfeng Hu,et al. LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy. , 2020, Life sciences.
[7] Lian-ji Zhou,et al. Circulating Expression Level of LncRNA Malat1 in Diabetic Kidney Disease Patients and Its Clinical Significance , 2020, Journal of diabetes research.
[8] Enyu Wang,et al. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. , 2020, Pharmacological research.
[9] Jianbo Wang,et al. Panax Notoginseng Ameliorates Podocyte EMT by Targeting the Wnt/β-Catenin Signaling Pathway in STZ-Induced Diabetic Rats , 2020, Drug design, development and therapy.
[10] N. Kawashita,et al. High-fat diet and streptozotocin in the induction of type 2 diabetes mellitus: a new proposal. , 2019, Anais da Academia Brasileira de Ciencias.
[11] V. Yang,et al. Podocyte-Specific Loss of Krüppel-Like Factor 6 Increases Mitochondrial Injury in Diabetic Kidney Disease , 2018, Diabetes.
[12] N. Zhang,et al. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice , 2018, Drug design, development and therapy.
[13] Hongyan Chen,et al. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] Y. Kulkarni,et al. Gallic acid attenuates type I diabetic nephropathy in rats. , 2018, Chemico-biological interactions.
[15] S. Gui,et al. Long noncoding RNA ENSRNOG00000037522 is involved in the podocyte epithelial-mesenchymal transition in diabetic rats , 2018, International journal of molecular medicine.
[16] J. Mendell,et al. Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.
[17] K. Tuttle,et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[18] A. Ghasemi,et al. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[19] A. Friedman,et al. Diagnosis and Management of Type 2 Diabetic Kidney Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[20] Haoran Dai,et al. Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy , 2017, Journal of diabetes research.
[21] J. Zhen,et al. LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose‐induced podocyte injury via its interplay with β‐catenin , 2017, Journal of cellular and molecular medicine.
[22] Guan-zhong Wu,et al. Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update , 2017, Renal failure.
[23] Shuai Yang,et al. Long Non-Coding RNA MALAT1 Mediates Transforming Growth Factor Beta1-Induced Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells , 2016, PloS one.
[24] G. Wolf,et al. Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction? , 2015, Cells.
[25] Youhua Liu,et al. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease , 2015, Nature Reviews Nephrology.
[26] Vivienne Zhu,et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging , 2014, BMC Research Notes.
[27] Lin Sun,et al. A Glimpse of the Pathogenetic Mechanisms of Wnt/β-Catenin Signaling in Diabetic Nephropathy , 2013, BioMed research international.
[28] D. Stolz,et al. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. , 2009, Journal of the American Society of Nephrology : JASN.
[29] G. Tesch,et al. Rodent models of streptozotocin‐induced diabetic nephropathy (Methods in Renal Research) , 2007, Nephrology.
[30] S. Shankland,et al. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.
[31] R. Wiggins,et al. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. , 2003, Journal of the American Society of Nephrology : JASN.
[32] G. Reaven,et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. , 2000, Metabolism: clinical and experimental.